IQVIA has agreed to acquire certain drug discovery services assets from Charles River Laboratories, including five sites providing in vitro discovery services, established lab-based New Approach Methodologies and a small molecule AI platform. IQVIA said the deal will expand IQVIA Laboratories’ end-to-end drug discovery capabilities from target identification through early safety assessment and is expected to close in the second quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IQVIA Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602250700BIZWIRE_USPR_____20260225_BW724183) on February 25, 2026, and is solely responsible for the information contained therein.